<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="data-paper" dtd-version="1.3"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_DIB107697 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEfx1 jpg ?><?FILEfx2 jpg ?><?FILEfx3 jpg ?><?FILEfx4 jpg ?><?FILEfx5 jpg ?><?FILEfx6 jpg ?><?FILEfx7 jpg ?><?FILEfx8 jpg ?><?FILEfx9 jpg ?><?FILEfx10 jpg ?><?FILEfx11 jpg ?><?FILEfx12 jpg ?><?FILEfx13 jpg ?><?FILEfx14 jpg ?><?FILEfx15 jpg ?><?FILEfx16 jpg ?><?FILEfx17 jpg ?><?FILEfx18 jpg ?><?FILEfx19 jpg ?><?FILEfx20 jpg ?><?FILEfx21 jpg ?><?FILEfx22 jpg ?><?FILEmmc1 docx ?><?FILEmmc2 zip ?><?FILEmmc3 zip ?><?FILEmmc4 zip ?><?FILEmmc5 zip ?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Data Brief</journal-id><journal-id journal-id-type="iso-abbrev">Data Brief</journal-id><journal-title-group><journal-title>Data in Brief</journal-title></journal-title-group><issn pub-type="epub">2352-3409</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8713121</article-id><article-id pub-id-type="pii">S2352-3409(21)00972-0</article-id><article-id pub-id-type="doi">10.1016/j.dib.2021.107697</article-id><article-id pub-id-type="publisher-id">107697</article-id><article-categories><subj-group subj-group-type="heading"><subject>Data Article</subject></subj-group></article-categories><title-group><article-title>Data on synthesis and structure&#x02013;activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Komeda</surname><given-names>Seiji</given-names></name><email>komedas@suzuka-u.ac.jp</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Yoneyama</surname><given-names>Hiroki</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Uemura</surname><given-names>Masako</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Tsuchiya</surname><given-names>Takahiro</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Hoshiyama</surname><given-names>Miyuu</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0006"><name><surname>Sakazaki</surname><given-names>Tomoya</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0007"><name><surname>Hiramoto</surname><given-names>Keiichi</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0008"><name><surname>Harusawa</surname><given-names>Shinya</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><aff id="aff0001"><label>a</label>Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan</aff><aff id="aff0002"><label>b</label>Department of Pharmaceutical Organic Chemistry, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author. <email>komedas@suzuka-u.ac.jp</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>10</day><month>12</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>2</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>12</month><year>2021</year></pub-date><volume>40</volume><elocation-id>107697</elocation-id><history><date date-type="received"><day>10</day><month>9</month><year>2021</year></date><date date-type="rev-recd"><day>7</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>8</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 The Authors</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><related-article related-article-type="article-reference" id="d35e14" ext-link-type="doi" xlink:href="10.1016/j.jinorgbio.2018.12.009"/><abstract id="abs0001"><p>In this data file, the synthetic procedures for the preparation of a series of anticancer tetrazolato-bridged dinuclear platinum(II) complexes ([{<italic>cis</italic>-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x003bc;-OH)(&#x003bc;-5-R-tetrazolato-<italic>N</italic>2,<italic>N</italic>3)]<sup>n+</sup> (<italic>n</italic>&#x000a0;=&#x000a0;1 or 2, tetrazolato-bridged complexes)) and of the bridging ligands of 5-substituted 1<italic>H</italic>-tetrazoles (5-R-1<italic>H</italic>-tetrazoles) are described. These compounds were characterized by <sup>1</sup>H-, <sup>13</sup>C-, <sup>19</sup>F- and <sup>195</sup>Pt-NMR spectroscopy and mass spectrometry.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Platinum</kwd><kwd>Tetrazole</kwd><kwd>Cancer</kwd><kwd>NMR</kwd><kwd>MS</kwd></kwd-group></article-meta></front><body><sec id="sec0001"><title>Specifications Table</title><p id="para0001">
<table-wrap position="float" id="utbl0001"><table frame="hsides" rules="groups"><tbody><tr><td valign="top">Subject</td><td valign="top">Chemistry</td></tr><tr><td valign="top">Specific subject area</td><td valign="top">Inorganic, organic and medicinal chemistry</td></tr><tr><td valign="top">Type of data</td><td valign="top">General protocol for synthesis with structure, NMR and MS data; in supplementary data &#x02013;NMR and mass spectra.</td></tr><tr><td valign="top">How data were acquired</td><td valign="top">For the tetrazolato-bridged dinuclear platinum(II) complexes, the <sup>1</sup>H-, <sup>13</sup>C-,<sup>19</sup>F-and <sup>195</sup>Pt-NMR spectra were recorded on (<sup>1</sup>H 400 MHz, Agilent, Santa Clara, CA, US) or a Varian NMR System (<sup>1</sup>H 600 MHz, Agilent) at 293 K. All <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were referenced to TSP [sodium 3-trimethylsilyl-propionate-2,2,3,3-d(4), <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;0], <sup>195</sup>Pt chemical shifts to K<sub>2</sub>PtCl<sub>4</sub> (<italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;1614), and <sup>19</sup>F chemical shifts to CF<sub>3</sub>COOH (<italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;76.55). MS was performed by using a micrOTOF-Q quadrupole&#x02013;time-of-flight mass spectrometer (Bruker, Billerica, MA, US) in the positive ion mode.<break/>For the 5-R-1<italic>H</italic>-tetrazole derivatives, <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were measured in CDCl<sub>3</sub> with tetramethylsilane (TMS) as the internal standard on a Varian Mercury-300 or Agilent 400-MR-DD2 spectrometers. <sup>19</sup>F-NMR spectra were recorded at 282 MHz (Varian Mercury-300) or 376 MHz (Agilent 400-MR-DD2), and the chemical shifts were measured relative to CF<sub>3</sub>CO<sub>2</sub>H as an external standard. High-resolution mass spectrometry spectra were determined by using a JMS-700(2) mass spectrometer (JEOL Ltd., Tokyo, Japan) operating in positive-ion mode. Melting points were determined using a Yanagimoto micromelting apparatus.</td></tr><tr><td valign="top">Data format</td><td valign="top">Raw and analyzed.</td></tr><tr><td valign="top">Parameters for data collection</td><td valign="top">Data were collected for characterisation purposes.</td></tr><tr><td valign="top">Description of data collection</td><td valign="top">Data were collected via the raw output files from the respective hardware. <sup>1</sup>H and <sup>13</sup>C or <sup>19</sup>F NMR spectra were recorded as fid files.</td></tr><tr><td valign="top">Data source location</td><td valign="top">Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan. 34.852990, 136.586422<break/>Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan. 34.864006, 135.574493</td></tr><tr><td valign="top">Data accessibility</td><td valign="top">With the article</td></tr><tr><td valign="top">Related research article</td><td valign="top">S. Komeda, H. Yoneyama, M. Uemura, T. Tsuchiya, M. Hoshiyama, T. Sakazaki, K. Hiramoto, S. Harusawa<break/>Synthesis and structure&#x02013;activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes: A small modification at tetrazole C5 markedly influences the <italic>in vivo</italic> antitumor efficacy<break/><italic>Journal of Inorganic Biochemistry</italic><break/><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jinorgbio.2018.12.009" id="interref0001">https://doi.org/10.1016/j.jinorgbio.2018.12.009</ext-link></td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec0002"><title>Value of the Data</title><p id="para9001">
<list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#x02022;</label><p id="para0002">The data contain the synthetic procedure for preparation of the anticancer tetrazolato-bridged dinuclear platinum(II) complexes [{<italic>cis</italic>-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x003bc;-OH)(&#x003bc;-5-R-tetrazolato-<italic>N</italic>2,<italic>N</italic>3)]<sup>n+</sup> (<italic>n</italic>&#x000a0;=&#x000a0;1 or 2) and their bridging ligands, 5-R-1<italic>H</italic>-tetrazoles.</p></list-item><list-item id="celistitem0002"><label>&#x02022;</label><p id="para0003">The data provide valuable guidance for researchers working on inorganic, organic and medicinal chemistry, and on drug-discovery research.</p></list-item><list-item id="celistitem0003"><label>&#x02022;</label><p id="para0004">The data serve as characterization of 15 original tetrazolato-bridged complexes and 5-R-1<italic>H</italic> tetrazoles.</p></list-item><list-item id="celistitem0004"><label>&#x02022;</label><p id="para0005">Some tetrazolato-bridged complexes may enter clinical trial as promising anticancer drug candidates.</p></list-item></list>
</p></sec><sec id="sec0003"><label>1</label><title>Data Description</title><p id="para0006">With a unique DNA binding mode <xref rid="bib0001" ref-type="bibr">[1]</xref>, <xref rid="bib0002" ref-type="bibr">[2]</xref>, <xref rid="bib0003" ref-type="bibr">[3]</xref>, <xref rid="bib0004" ref-type="bibr">[4]</xref>, <xref rid="bib0005" ref-type="bibr">[5]</xref>, <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref> and a different cellular uptake pathway [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0010" ref-type="bibr">10</xref>] than currently available platinum-based drugs, tetrazolato-bridged dinuclear platinum(II) complexes (tetrazolato-bridged complexes) with the general formula [{<italic>cis</italic>-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x003bc;-OH)(&#x003bc;-5-R-tetrazolato-<italic>N</italic>2,<italic>N</italic>3)]<sup>2+</sup> (<xref rid="fig0001" ref-type="fig">Fig.&#x000a0;1</xref>) are currently being developed as next-generation platinum-based drugs, <xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>, <xref rid="bib0014" ref-type="bibr">[14]</xref> and many are reported to be effective against cancers with intrinsic <xref rid="bib0005" ref-type="bibr">[5]</xref> or acquired [<xref rid="bib0003" ref-type="bibr">3</xref>,<xref rid="bib0010" ref-type="bibr">10</xref>] resistance to platinum-based drugs. Complexes <bold>1</bold>&#x02013;<bold>15</bold> were newly synthesized, along with seven 5-R-1<italic>H</italic>-tetrazole derivatives (<bold>SH</bold>; <xref rid="fig0002" ref-type="fig">Fig.&#x000a0;2</xref>), which were synthesized by the reactions of sodium azide and inactive nitriles in DMF in a microwave reactor to provide efficient transformation into tetrazoles. These newly prepared compounds were characterized by using <sup>1</sup>H-, <sup>13</sup>C-, <sup>19</sup>F- or <sup>195</sup>Pt-NMR spectroscopy and mass spectrometry.<fig id="fig0001"><label>Fig. 1</label><caption><p>Structures of the series of tetrazolato-bridged dinuclear Pt(II) complexes, among which 15 new tetrazolato-bridged complexes were newly synthesized.</p></caption><alt-text id="alt0023">Fig 1</alt-text><graphic xlink:href="gr1"/></fig><fig id="fig0002"><label>Fig. 2</label><caption><p>Structures of newly synthesized 5-substituted 1<italic>H</italic>-tetrazoles (5-R-1<italic>H</italic>-tetrazoles)</p></caption><alt-text id="alt0024">Fig 2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec0004"><label>2</label><title>Experimental Design, Materials and Methods</title><sec id="sec0005"><label>2.1</label><title>General information</title><sec id="sec0006"><label>2.1.1</label><title>Synthesis of tetrazolato-bridged dinuclear Pt(II) complexes</title><p id="para0007">K<sub>2</sub>PtCl<sub>4</sub> was obtained from Tanaka Kikinzoku Kogyo K.K. (Tokyo, Japan), and 5-(trifluoromethyl)-1<italic>H</italic>-tetrazole was purchased from Fluorochem Ltd (Hadfield, UK). The tetrazole derivatives <xref rid="bib0013" ref-type="bibr">[13]</xref> (ethyl 1<italic>H</italic>-tetrazole-5-carboxylate, propyl 1<italic>H</italic>-tetrazole-5-aceate, 5-(cyclohexyl)-1<italic>H</italic>-tetrazole and 5-(adamantyl)-1<italic>H</italic>-tetrazole) were prepared according to published methods. Other tetrazole derivatives (<bold>SH20, SH22, SH23, SH33, SH34, SH40</bold> and <bold>SH41</bold>) were newly prepared and synthetic procedures are described below. The <sup>1</sup>H-NMR spectra of <bold>1, 2, 4</bold>-<bold>12, 14</bold> and <bold>15</bold>, <sup>13</sup>C- and <sup>195</sup>Pt-NMR spectra of <bold>1</bold>&#x02013;<bold>15</bold>, and <sup>19</sup>F-NMR spectra of <bold>13</bold>&#x02013;<bold>15</bold> were recorded on (<sup>1</sup>H 400 MHz, Agilent, Santa Clara, CA, US) or a Varian NMR System (<sup>1</sup>H 600 MHz, Agilent) at 293 K and are shown in Fig. S1&#x02013;S4. All <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were referenced to TSP [sodium 3-trimethylsilyl-propionate-2,2,3,3-d(4), <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;0], <sup>195</sup>Pt chemical shifts to K<sub>2</sub>PtCl<sub>4</sub> (<italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;1614), and <sup>19</sup>F chemical shifts to CF<sub>3</sub>COOH (<italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;76.55). For <bold>1</bold>&#x02013;<bold>15,</bold> MS was performed by using a micrOTOF-Q quadrupole&#x02013;time-of-flight mass spectrometer (Bruker, Billerica, MA, US) in the positive ion mode, and the mass spectra are shown in Fig. S5.</p></sec><sec id="sec0007"><label>2.1.2</label><title>Synthesis of 5-R-1H-Tetrazoles</title><p id="para0008">Microwave-assisted reactions were performed in a Milestone MultiSYNTH multimodal reactor with thermal control. Reactions with air- and moisture-sensitive compounds were carried out under an Ar atmosphere. Anhydrous solvents were purchased from WAKO Chemical Co. Solvents were removed in a rotary evaporator under reduced pressure. Fuji Silysia FL-60D silica gel was used for flash column chromatography. TLC was performed on pre-coated TLC plates (WAKO silica gel 70 F<sub>254</sub>). <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were measured in CDCl<sub>3</sub> with tetramethylsilane (TMS) as the internal standard on a Varian Mercury-300 or Agilent 400-MR-DD2 spectrometers. <sup>19</sup>F-NMR spectra were recorded at 282 MHz (Varian Mercury-300) or 376 MHz (Agilent 400-MR-DD2), and the chemical shifts were measured relative to CF<sub>3</sub>CO<sub>2</sub>H as an external standard. High-resolution mass spectrometry spectra were determined by using a JMS-700(2) mass spectrometer (JEOL Ltd., Tokyo, Japan) operating in positive-ion mode. Melting points were determined using a Yanagimoto micromelting apparatus and were uncorrected.</p></sec></sec><sec id="sec0008"><label>2.2</label><title>General procedure</title><sec id="sec0009"><label>2.2.1</label><title>Synthesis of tetrazolato-bridged dinuclear Pt(II) complexes</title><p id="para0009">5-R-1<italic>H</italic>-tetrazole (1.79 mmol) was dissolved in 5 mL MeOH and added to a solution of [<italic>cis</italic>-Pt(NH<sub>3</sub>)<sub>2</sub>(&#x000b5;-OH)]<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub> (1.0 g, 1.62 mmol) in 25 mL of water. The solution was stirred and heated at 40&#x000a0;&#x000b0;C for 24&#x000a0;h in the dark and then filtered; the filtrate was evaporated to dryness using a centrifugal evaporator (CVE-3000; Tokyo Rikakikai Co, Ltd). The resulting powder was collected on a glass filter, washed with 2-propanol and diethyl ether, and recrystallised from water (compound <bold>1, 2, 4, 5</bold>-<bold>7, 11</bold>) or methanol (<bold>12, 13</bold>) using the centrifugal evaporator. For the synthesis of <bold>3,</bold> a 1 M lithium hydroxide solution (300&#x000a0;&#x003bc;L) was added to a solution prepared by dissolving 0.20&#x000a0;g of compound <bold>1</bold> in 5 mL of distilled water, which was stirred for approximately 10 min at room temperature. The resulting white precipitate was filtered and washed with 2-propanol and diethyl ether, recovered by filtration, dried in a vacuum desiccator. For the synthesis of <bold>9</bold> or <bold>10</bold>, a 1 M lithium hydroxide solution (300&#x000a0;&#x003bc;L) was added to a solution prepared by dissolving 0.20&#x000a0;g of compound <bold>4</bold> or <bold>8</bold> in 5 mL of distilled water, and the resulting solution was stirred for approximately 10 min at room temperature. The pH of the solution was adjusted to 7 with 0.1&#x000a0;M aqueous nitric acid and then lyophilized. The resulting white powder was washed with 2-propanol and diethyl ether. The dried powder was re-dissolved, and the pH of the solution was adjusted to 7 with 0.1&#x000a0;M aqueous nitric acid, and the solution was then evaporated to dryness. This process was repeated three times to replace any remaining calboxylate ions (as counterions) with nitrate ions. The resulting white powder was washed with 2-propanol and diethyl ether. For the synthesis of <bold>14</bold> or <bold>15</bold>, a solution of 5-alkyl-1<italic>H-</italic>tetrazole (1.79&#x000a0;mmol) in 15 mL of MeOH was added to a solution of [<italic>cis</italic>-Pt(NH<sub>3</sub>)<sub>2</sub>(&#x000b5;-OH)]<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub> (1.0&#x000a0;g, 1.62&#x000a0;mmol) in 30&#x000a0;mL of water. The solution was stirred vigorously at 50&#x000a0;&#x000b0;C for 48&#x000a0;h in the dark and then lyophilized. The resulting white powder was collected on a glass filter, washed with 2-propanol and diethyl ether, and recrystallized from methanol.</p><p id="para0010"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-ethyltetrazolato-5-carboxylate-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>1</bold>)<inline-graphic xlink:href="fx1.gif"/></p><p id="para0011">Yield: 384 mg (32.0%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;1.42 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.4 Hz), 4.52 (q, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;16.1 (1C), 66.7 (1C), 159.2 (1C), 161.6 (1C). <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2186. MS (ESI, Fig. S5.1) [M-H]<sup>+</sup>: 615.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-ethyl tetrazolato-5-carboxylate<italic>-N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0012"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-propyltetrazolato-5-acetate-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>2</bold>)<inline-graphic xlink:href="fx2.gif"><alt-text id="at0020b">Image 2</alt-text></inline-graphic></p><p id="para0013">Yield: 212 mg (17.0%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;0.91 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.4 Hz), 1.67 (sx, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.4 Hz), 4.12 (s, 2H), 4.16 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.4 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;12.4 (1C), 24.1 (1C), 33.6 (1C), 71.0 (1C), 161.8 (1C), 174.3 (1C). <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2179. MS (ESI, Fig. S5.1) [M-H]<sup>+</sup>: 643.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-propyl tetrazolato<italic>-</italic>5-acetate-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0014"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-tetrazolato-5-carboxylate-N2,N3)](NO<sub>3</sub>)</italic> (<bold>3</bold>)<inline-graphic xlink:href="fx3.gif"><alt-text id="at3020b">Image 3</alt-text></inline-graphic></p><p id="para0015">Yield: 171 mg (89.0%). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;166.6 (1C), 184.9 (1C). <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.1): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2181. MS (ESI, Fig. S5.1) [M]: 587.0 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-tetrazolato-5-carboxylate<italic>-N2,N3</italic>)]<sup>+</sup>)</p><p id="para0016"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(acetoxy)methyltetrazolato-N2,N3](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>4</bold>)<inline-graphic xlink:href="fx4.gif"><alt-text id="at4020b">Image 4</alt-text></inline-graphic></p><p id="para0017">Yield: 138 mg (11.3%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;2.15 (s, 3H), 5.40 (s, 2H). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;23.0, 59.5, 163.4, 176.2. <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2181. MS (ESI, Fig. S5.1) [M-H]<sup>+</sup>: 615.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(acetoxy)methyltetrazolato-<italic>N2,N3</italic>]<sup>2+</sup>)</p><p id="para0018">
<italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(propionyloxy)methyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub> (</italic>
<bold><italic>5</italic></bold>
<italic>)</italic>
<inline-graphic xlink:href="fx5.gif"><alt-text id="at5020b">Image 5</alt-text></inline-graphic>
</p><p id="para0019">Yield: 115 mg (9.6%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;1.11 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 2.46 (2H, q), 5.41 (s, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;11.0, 29.9, 59.4, 163.5, 179.7. <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2181. MS (ESI, Fig. S5.1) [M-H]<sup>+</sup>: 629.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(propionyloxy)methyl tetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0020"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(butyryloxy)methyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>6</bold>)<inline-graphic xlink:href="fx6.gif"><alt-text id="at6020b">Image 6</alt-text></inline-graphic></p><p id="para0021">Yield: 263 mg (21.5%). <sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O, Fig. S1.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;0.91 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 1.62 (sx, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 2.43 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 5.41 (2H, s). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;15.6, 20.7, 38.3, 59.4, 163.5, 178.9. <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2181. MS (ESI, Fig. S5.2) [M-H]<sup>+</sup>: 643.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(butyryloxy)methyltetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0022"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-(propionyloxy)ethyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>7</bold>)<inline-graphic xlink:href="fx7.gif"><alt-text id="at7020b">Image 7</alt-text></inline-graphic></p><p id="para0023">Yield: 403 mg (33.0%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;1.06 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 2.36 (q, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 3.28 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz), 4.50 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;12.6, 17.8, 35.3, 56.4, 160.5, 175.9. <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.2): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2179. MS (ESI, Fig. S5.2) [M-H]<sup>+</sup>: 643.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-(propionyloxy)ethyltetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0024"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(butyryloxy)ethyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>8</bold>)<inline-graphic xlink:href="fx8.gif"><alt-text id="at8020b">Image 8</alt-text></inline-graphic></p><p id="para0025">Yield: 93 mg (6.6%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;0.86 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 1.55 (sx, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 2.32 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 3.29 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz), 4.51 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;15.6, 20.8, 27.6, 38.5, 65.2, 165.4, 179.6. <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2179. MS (ESI, Fig. S5.2) [M-H]<sup>+</sup>: 657.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(butyryloxy)methyl tetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0026"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-hydroxymethyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>9</bold>)<inline-graphic xlink:href="fx9.gif"><alt-text id="at9020b">Image 9</alt-text></inline-graphic></p><p id="para0027">Yield: 28 mg (15.0%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;4.89 (s, 2H). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;57.4, 166.9. <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2181. MS (ESI, Fig. S5.2) [M-H]<sup>+</sup>: 573.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-hydroxymethyltetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0028"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-hydroxyethyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>10</bold>)<inline-graphic xlink:href="fx10.gif"><alt-text id="at8820b">Image 10</alt-text></inline-graphic></p><p id="para0029">Yield: 30 mg (18.0%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;3.13 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;6.8 Hz), 3.97 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.8 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;30.7, 62.1, 166.2. <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2178. MS (ESI, Fig. S5.2) [M-H]<sup>+</sup>: 587.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-hydroxyethyltetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0030"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-mono-fluoromethyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>11</bold>)<inline-graphic xlink:href="fx11.gif"><alt-text id="at8920b">Image 11</alt-text></inline-graphic></p><p id="para0031">Yield: 320 mg (28.2%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;5.67 (d, 2H, <sup>2</sup><italic>J</italic><sub>HF</sub>&#x000a0;=&#x000a0;47 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;77.6 (d, <sup>1</sup><italic>J</italic><sub>CF</sub>&#x000a0;=&#x000a0;164 Hz), 163.2. <sup>19</sup>F NMR (564 MHz, D<sub>2</sub>O, Fig. S3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;215.1 (t, 1F, <sup>2</sup><italic>J</italic><sub>FH</sub>&#x000a0;=&#x000a0;48 Hz). <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2183. MS (ESI, Fig. S5.3) [M-H]<sup>+</sup>: 575.0 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-monofluoromethyltrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0032"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-difluoromethyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>12</bold>)<inline-graphic xlink:href="fx12.gif"><alt-text id="at78920b">Image 12</alt-text></inline-graphic></p><p id="para0033">Yield: 262 mg (22.5%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O, Fig. S1.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;7.15 (t, 1H, <sup>2</sup><italic>J</italic><sub>HF</sub>&#x000a0;=&#x000a0;53 Hz). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;110.8 (t, <sup>1</sup><italic>J</italic><sub>CF</sub>&#x000a0;=&#x000a0;238 Hz), 161.7 (d, <sup>2</sup><italic>J</italic><sub>CF</sub>&#x000a0;=&#x000a0;28.1 Hz). <sup>19</sup>F NMR (564 MHz, D<sub>2</sub>O, Fig. S3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;116.8 (d, 2F, <sup>2</sup><italic>J</italic><sub>FH</sub>&#x000a0;=&#x000a0;54 Hz). <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2184. MS (ESI, Fig. S5.3) [M-H]<sup>+</sup>: 593.0 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-difluoromethyltrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0034"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-trifluoromethyl tetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>13</bold>)<inline-graphic xlink:href="fx13.gif"><alt-text id="at79913b">Image 13</alt-text></inline-graphic></p><p id="para0035">Yield: 259 mg (21.7%). <sup>13</sup>C NMR (151 MHz, D<sub>2</sub>O, Fig. S2.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;121.5 (q, <sup>1</sup><italic>J</italic><sub>CF</sub>&#x000a0;=&#x000a0;269 Hz), 158.8 (d, <sup>2</sup><italic>J</italic><sub>CF</sub>&#x000a0;=&#x000a0;42 Hz). <sup>19</sup>F NMR (564 MHz, D<sub>2</sub>O, Fig. S3): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;62.7 (s, 3F). <sup>195</sup>Pt NMR (129 MHz, D<sub>2</sub>O, Fig. S4.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2184. MS (ESI, Fig. S5.3) [M-H]<sup>+</sup>: 611.0 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-trifluoromethyltrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0036"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-cyclohexyltetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>14</bold>)<inline-graphic xlink:href="fx14.gif"><alt-text id="at79914b">Image 14</alt-text></inline-graphic></p><p id="para0037">Yield: 430 mg (35.3%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD, Fig. S1.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;1.29 (m, 1H), 1.41 (m, 2H), 1.55 (m, 2H), 1.72 (m, 1H), 1.80 (m, 2H), 1.98 (m, 2H), 2.98 (1H, m). <sup>13</sup>C NMR (CD<sub>3</sub>OD, Fig. S2.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;28.2, 34.1, 37.7, 172.6. <sup>195</sup>Pt NMR (CD<sub>3</sub>OD, Fig. S4.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2172. MS (ESI, Fig. S5.3) [M-H]<sup>+</sup>: 625.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-cyclohexyltetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p><p id="para0038"><italic>[{cis-Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(adamantan-1-yl)tetrazolato-N2,N3)](NO<sub>3</sub>)<sub>2</sub></italic> (<bold>15</bold>)<inline-graphic xlink:href="fx15.gif"><alt-text id="at79915b">Image 15</alt-text></inline-graphic></p><p id="para0039">Yield: 364 mg (28.0%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD, Fig. S1.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;1.76-1.84 (m, 6H), 2.01 (m, 6H), 2.07 (m, 3H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, Fig. S2.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;30.7, 36.2, 38.7, 43.7, 175.8. <sup>195</sup>Pt NMR (D<sub>2</sub>O, Fig. S4.4): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;2175. MS (ESI, Fig. S5.3) [M-H]<sup>+</sup>: 677.1 (M&#x000a0;=&#x000a0;[{<italic>cis-</italic>Pt(NH<sub>3</sub>)<sub>2</sub>}<sub>2</sub>(&#x000b5;-OH)(&#x000b5;-5-(adamantan-1-yl)tetrazolato-<italic>N2,N3</italic>)]<sup>2+</sup>)</p></sec><sec id="sec0010"><label>2.2.2</label><title>Synthesis of 1H-Tetrazole derivatives</title><p id="para0040">NaN<sub>3</sub> (975 mg, 15 mmol) and Et<sub>3</sub>N<sup>.</sup>HCl (2065 mg, 15 mmol) were added to a solution of the nitrile (5 mmol) in PhNO<sub>2</sub> (10 mL). The reaction mixture was exposed to MW irradiation at 100&#x000b0;C for 2 h. The reaction mixture treated with EtOAc (100 mL), and extracted with 4% aq. NaOH (50&#x000a0;mL&#x000a0;&#x000d7;&#x000a0;3). The combined aqueous layers were washed with EtOAc, acidified with 6<italic>N</italic> HCl, and extracted with EtOAc (100 mL&#x000a0;&#x000d7;&#x000a0;2). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and evaporated to afford a crude residue that was purified by using column chromatography on silica gel with EtOAc <xref rid="bib0015" ref-type="bibr">[15]</xref>. For the synthesis of <bold>SH40</bold>, to a solution of 2-fluoroacetonitrile (885 mg, 15 mmol) in DMF (10 mL) NaN<sub>3</sub> (1950 mg, 30 mmol) and Et<sub>3</sub>N&#x000b7;HCl (4120 mg, 30 mmol) were added. After stirring for 3 h at 80 &#x000b0;C, the reaction mixture was dissolved in EtOAc (150 mL). The organic layer was washed with 2<italic>N</italic> HCl (50 mL&#x000a0;&#x000d7;&#x000a0;4) and then brine, and then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford a crude residue that was recrystallized from hexane to give white needles (m.p. 79&#x02013;80 &#x000b0;C). For the synthesis of <bold>SH41</bold>,to a solution of 2,2-difluoroacetonitrile (1155 mg, 15 mmol) in DMF (10 mL) NaN<sub>3</sub> (1950 mg, 30 mmol) and Et<sub>3</sub>N&#x000b7;HCl (4120 mg, 30 mmol) were added. After stirring for 20 h at r.t., the reaction mixture was dissolved in EtOAc (150 mL). The organic layer was washed with 2<italic>N</italic> HCl (50 mL&#x000a0;&#x000d7;&#x000a0;4), brine, and then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford a crude residue that was recrystallized from hexane to give prisms of compound (m.p. 98&#x02013;99&#x000a0;&#x000b0;C).</p><p id="para0041">
<italic>(1H-tetrazol-5-yl)methyl acetate (</italic>
<bold><italic>SH23</italic></bold>
<italic>, 5-[(acetoxy)methyl]-1H-tetrazole)</italic>
<inline-graphic xlink:href="fx16.gif"><alt-text id="at79916b">Image 16</alt-text></inline-graphic>
</p><p id="para0042">Yield: 450 mg (63%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;2.17 (s, 3H), 5.55 (s, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;20.5, 55.0, 153.1, 171.3.</p><p id="para0043">
<italic>(1H-tetrazol-5-yl)methyl propionate (</italic>
<bold><italic>SH22</italic></bold>
<italic>, 5-[(propionyloxy)methyl]-1H-tetrazole)</italic>
<inline-graphic xlink:href="fx17.gif"><alt-text id="at79917b">Image 17</alt-text></inline-graphic>
</p><p id="para0044">Yield: 385 mg (49%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;1.12 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 2.44 (q, 2H. <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 5.59 (s, 2H). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;8.6, 27.0, 54.8, 153.2, 174.5. HRMS (EI): <italic>m</italic>/<italic>z</italic> [M<sup>+</sup>] calcd for C<sub>5</sub>H<sub>9</sub>N<sub>4</sub>O<sub>2</sub>: 157.0725; found: 157.0730.</p><p id="para0045">
<italic>(1H-tetrazol-5-yl)methyl butyrate (</italic>
<bold><italic>SH34</italic></bold>
<italic>, 5-[(butyryloxy)methyl]-1H-tetrazole)</italic>
<inline-graphic xlink:href="fx18.gif"><alt-text id="at79918b">Image 18</alt-text></inline-graphic>
</p><p id="para0046">Yield: 600 mg (70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;0.91 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 1.64 (sx, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 2.39 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.6 Hz), 5.60 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;13.4, 18.0, 35.4, 54.7, 153.2, 173.6. HRMS (EI): <italic>m</italic>/<italic>z</italic> [M<sup>+</sup>] calcd for C<sub>6</sub>H<sub>11</sub>N<sub>4</sub>O<sub>2</sub>: 171.0882; found: 171.0879.</p><p id="para0047">
<italic>2-(1H-tetrazol-5-yl)ethyl propionate (</italic>
<bold><italic>SH20</italic></bold>
<italic>, 5-[(propionyloxy)ethyl]-1H-tetrazole)</italic>
<inline-graphic xlink:href="fx19.gif"><alt-text id="at79919b">Image 19</alt-text></inline-graphic>
</p><p id="para0048">Yield: 404 mg (47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;1.09 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 2.33 (q, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 3.49 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz), 4.58 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz). <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;9.2, 24.4, 28.0, 62.2, 155.4, 175.6. HRMS (EI): <italic>m</italic>/<italic>z</italic> [M<sup>+</sup>] calcd for C<sub>6</sub>H<sub>11</sub>N<sub>4</sub>O<sub>2</sub>: 171.0882; found: 171.0881.</p><p id="para0049">
<italic>2-(1H-tetrazol-5-yl)ethyl butyrate (</italic>
<bold><italic>SH33</italic></bold>
<italic>, 5-[(butyryloxy)ethyl]-1H-tetrazole)</italic>
<inline-graphic xlink:href="fx20.gif"><alt-text id="at79920b">Image 20</alt-text></inline-graphic>
</p><p id="para0050">Yield: 482 mg (52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;0.88 (t, 3H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 1.57 (sx, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 2.28 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;7.2 Hz), 3.49 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz), 4.58 (t, 2H, <italic>J</italic>&#x000a0;=&#x000a0;6.4 Hz). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;13.5, 18.2, 23.8, 35.9, 60.9, 154.2, 174.0. HRMS (EI): <italic>m</italic>/<italic>z</italic> [M<sup>+</sup>] calcd for C<sub>7</sub>H<sub>13</sub>N<sub>4</sub>O<sub>2</sub>: 185.1039; found: 185.1037.</p><p id="para0051">
<italic>5-(Fluoromethyl)-1H-tetrazole (<bold>SH40</bold>)</italic>
<inline-graphic xlink:href="fx21.gif"><alt-text id="at79921b">Image 21</alt-text></inline-graphic>
</p><p id="para0052">Yield: 966 mg (63%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;5.75 (d, 2H, <italic>J</italic>&#x000a0;=&#x000a0;46.8 Hz). <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;75.0 (d, <italic>J</italic>&#x000a0;=&#x000a0;165.0 Hz), 155.0. <sup>19</sup>F NMR (282 MHz, CD<sub>3</sub>OD): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;221.7 (t, <italic>J</italic>&#x000a0;=&#x000a0;46.8 Hz). HRMS (EI): <italic>m</italic>/<italic>z</italic> [M<sup>+</sup>] calcd for C<sub>2</sub>H<sub>3</sub>FN<sub>4</sub>: 102.0342; found: 102.0339.</p><p id="para0053">
<italic>5-(Difluoromethyl)-1H-tetrazole (<bold>SH41</bold>)</italic>
<inline-graphic xlink:href="fx22.gif"><alt-text id="at79922b">Image 22</alt-text></inline-graphic>
</p><p id="para0054">Yield: 1419 mg (79%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;7.24 (t, 1H, <italic>J</italic>&#x000a0;=&#x000a0;52.8 Hz). <sup>13</sup>C-NMR (100 MHz, CD<sub>3</sub>OD): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;109.5 (t, <italic>J</italic>&#x000a0;=&#x000a0;236.0 Hz), 156.6. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD): <italic>&#x003b4;</italic>&#x000a0;=&#x000a0;&#x02212;117.2 (d, <italic>J</italic>&#x000a0;=&#x000a0;52.8 Hz). HRMS (EI): <italic>m</italic>/<italic>z</italic> [M<sup>+</sup>] calcd for C<sub>2</sub>H<sub>2</sub>F<sub>2</sub>N<sub>4</sub>: 120.0248; found: 120.0243.</p></sec></sec></sec><sec id="sec0010a"><title>CRediT authorship contribution statement</title><p id="para0054a"><bold>Seiji Komeda:</bold> Funding acquisition, Project administration, Supervision, Investigation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. <bold>Hiroki Yoneyama:</bold> Investigation, Writing &#x02013; original draft. <bold>Masako Uemura:</bold> Investigation, Writing &#x02013; original draft. <bold>Takahiro Tsuchiya:</bold> Investigation. <bold>Miyuu Hoshiyama:</bold> Investigation. <bold>Tomoya Sakazaki:</bold> Investigation. <bold>Keiichi Hiramoto:</bold> Investigation, Writing &#x02013; original draft. <bold>Shinya Harusawa:</bold> Supervision, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="para0061">The authors declare that they have no competing interests.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Kanbe</surname><given-names>T.</given-names></name><name><surname>Chikuma</surname><given-names>M.</given-names></name><name><surname>Yoshikawa</surname><given-names>K.</given-names></name><name><surname>Imanaka</surname><given-names>T.</given-names></name></person-group><article-title>Highly efficient DNA compaction mediated by an <italic>in vivo</italic> antitumor-active tetrazolato-bridged dinuclear platinum(II) complex</article-title><source>Inorg. Chem.</source><volume>50</volume><year>2011</year><fpage>11729</fpage><lpage>11735</lpage><pub-id pub-id-type="doi">10.1021/ic2017165</pub-id><pub-id pub-id-type="pmid">22004345</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Chikuma</surname><given-names>M.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name></person-group><article-title>A circular dichroism study uncovers a two-step interaction of antitumor azolato-bridged dinuclear platinum(II) complexes with calf thymus DNA</article-title><source>Metallomics</source><volume>4</volume><year>2012</year><fpage>641</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1039/c2mt20022h</pub-id><pub-id pub-id-type="pmid">22538714</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Nishio</surname><given-names>K.</given-names></name><name><surname>Chikuma</surname><given-names>M.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name></person-group><article-title>An <italic>in vivo</italic> highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex largely circumvents <italic>in vitro</italic> cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles</article-title><source>Metallomics</source><volume>4</volume><year>2012</year><fpage>686</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1039/c2mt20026k</pub-id><pub-id pub-id-type="pmid">22473092</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Yoshikawa</surname><given-names>K.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Mino</surname><given-names>Y.</given-names></name><name><surname>Chikuma</surname><given-names>M.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name></person-group><article-title>Second- and higher-order structural changes of DNA induced by antitumor-active tetrazolato-bridged dinuclear platinum(II) complexes with different types of 5-substituent</article-title><source>J. Inorg. Biochem.</source><volume>127</volume><year>2013</year><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2013.05.004</pub-id><pub-id pub-id-type="pmid">23725767</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Takayama</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Odani</surname><given-names>A.</given-names></name><name><surname>Yamori</surname><given-names>T.</given-names></name><name><surname>Chikuma</surname><given-names>M.</given-names></name></person-group><article-title>Synthesis of antitumor azolato-bridged dinuclear platinum(II) complexes with <italic>in vivo</italic> antitumor efficacy and unique <italic>in vitro</italic> cytotoxicity profiles</article-title><source>Metallomics</source><volume>5</volume><year>2013</year><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1039/c3mt00040k</pub-id><pub-id pub-id-type="pmid">23608770</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name></person-group><article-title>Kinetic analysis of and platinum(II) migration in the reactions of tetrazolato-bridged dinuclear platinum(II) complexes with nucleotides</article-title><source>J. Inorg. Biochem.</source><volume>177</volume><year>2017</year><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2017.08.010</pub-id><pub-id pub-id-type="pmid">28893417</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>R.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Shimura</surname><given-names>M.</given-names></name><name><surname>Tamura</surname><given-names>S.</given-names></name><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Nishimura</surname><given-names>K.</given-names></name><name><surname>Rogge</surname><given-names>R.</given-names></name><name><surname>Matsunaga</surname><given-names>A.</given-names></name><name><surname>Hiratani</surname><given-names>I.</given-names></name><name><surname>Takata</surname><given-names>H.</given-names></name><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Iida</surname><given-names>Y.</given-names></name><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Hansen</surname><given-names>J.C.</given-names></name><name><surname>Yamauchi</surname><given-names>K.</given-names></name><name><surname>Kanemaki</surname><given-names>M.T.</given-names></name><name><surname>Maeshima</surname><given-names>K.</given-names></name></person-group><article-title>Chromatin folding and DNA replication inhibition mediated by a highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year><fpage>24712</fpage><pub-id pub-id-type="doi">10.1038/srep24712</pub-id><pub-id pub-id-type="pmid">27094881</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Yoneyama</surname><given-names>H.</given-names></name><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Muramatsu</surname><given-names>A.</given-names></name><name><surname>Okamoto</surname><given-names>N.</given-names></name><name><surname>Konishi</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><name><surname>Takagi</surname><given-names>A.</given-names></name><name><surname>Fukuda</surname><given-names>W.</given-names></name><name><surname>Imanaka</surname><given-names>T.</given-names></name><name><surname>Kanbe</surname><given-names>T.</given-names></name><name><surname>Harusawa</surname><given-names>S.</given-names></name><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Yoshikawa</surname><given-names>K.</given-names></name></person-group><article-title>Specific conformational change in giant DNA caused by anticancer tetrazolato-bridged dinuclear platinum(II) complexes: middle-length alkyl substituents exhibit minimum effect</article-title><source>Inorg. Chem.</source><volume>56</volume><year>2017</year><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1021/acs.inorgchem.6b02239</pub-id><pub-id pub-id-type="pmid">28045514</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>Y.</given-names></name><name><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name><surname>Kenmotsu</surname><given-names>T.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Yoshikawa</surname><given-names>K.</given-names></name></person-group><article-title>Conformational transition of DNA by dinuclear Pt (II) complexes causes cooperative inhibition of gene expression</article-title><source>Chem. Phys. Lett.</source><volume>678</volume><year>2017</year><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.cplett.2017.04.039</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Hoshiyama</surname><given-names>M.</given-names></name><name><surname>Furukawa</surname><given-names>A.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Higuchi</surname><given-names>Y.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name></person-group><article-title>Highly efficient uptake into cisplatin-resistant cells and the isomerization upon coordinative DNA binding of anticancer tetrazolato-bridged dinuclear platinum(II) complexes</article-title><source>Metallomics</source><volume>7</volume><year>2015</year><fpage>1488</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1039/c5mt00174a</pub-id><pub-id pub-id-type="pmid">26393664</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Komeda</surname><given-names>S.</given-names></name></person-group><article-title>Unique platinum-DNA interactions may lead to more effective platinum-based antitumor drugs</article-title><source>Metallomics</source><volume>3</volume><year>2011</year><fpage>650</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1039/c1mt00012h</pub-id><pub-id pub-id-type="pmid">21519596</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>Y.L.</given-names></name><name><surname>Chikuma</surname><given-names>M.</given-names></name></person-group><article-title>A tetrazolato-bridged dinuclear platinum(II) complex exhibits markedly high <italic>in vivo</italic> antitumor activity against pancreatic cancer</article-title><source>ChemMedChem</source><volume>6</volume><year>2011</year><fpage>987</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201100141</pub-id><pub-id pub-id-type="pmid">21500354</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Yoneyama</surname><given-names>H.</given-names></name><name><surname>Usami</surname><given-names>Y.</given-names></name><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Harusawa</surname><given-names>S.</given-names></name></person-group><article-title>Efficient transformation of inactive nitriles into 5-substituted 1H-tetrazoles using microwave irradiation and their applications</article-title><source>Synthesis</source><volume>45</volume><year>2013</year><fpage>1051</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1318476</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Komeda</surname><given-names>S.</given-names></name><name><surname>Yoneyama</surname><given-names>H.</given-names></name><name><surname>Uemura</surname><given-names>M.</given-names></name><name><surname>Tsuchiya</surname><given-names>T.</given-names></name><name><surname>Hoshiyama</surname><given-names>M.</given-names></name><name><surname>Sakazaki</surname><given-names>T.</given-names></name><name><surname>Hiramoto</surname><given-names>K.</given-names></name><name><surname>Harusawa</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and structure&#x02013;activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes: a small modification at tetrazole C5 markedly influences the <italic>in vivo</italic> antitumor efficacy</article-title><source>J. Inorg. Biochem.</source><year>2019</year><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2018.12.009</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>J.</given-names></name><name><surname>Artamonova</surname><given-names>T.V.</given-names></name><name><surname>V&#x000e1;vrov&#x000e1;</surname><given-names>K.</given-names></name><name><surname>Koldobskii</surname><given-names>G.I.</given-names></name><name><surname>Hrabalek</surname><given-names>A.</given-names></name></person-group><article-title>Practical synthesis of 5-substituted tetrazoles under microwave irradiation</article-title><source>Synthesis</source><volume>2009</volume><year>2009</year><fpage>2175</fpage><lpage>2178</lpage><pub-id pub-id-type="doi">10.1055/s-0029-1216840</pub-id></element-citation></ref></ref-list><sec id="sec0012" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0055a">
<supplementary-material content-type="local-data" id="ecom0001"><media xlink:href="mmc1.docx"><alt-text>Image, application 1</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0002"><media xlink:href="mmc2.zip"><alt-text>Image, application 2</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0003"><media xlink:href="mmc3.zip"><alt-text>Image, application 3</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0004"><media xlink:href="mmc4.zip"><alt-text>Image, application 4</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0005"><media xlink:href="mmc5.zip"><alt-text>Image, application 5</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgments</title><p id="para0060">This work was supported by <funding-source id="gs0001">JSPS KAKENHI</funding-source> Grant Number 19K07018. (SK and MU).</p></ack><fn-group><fn id="sec0011" fn-type="supplementary-material"><p id="para0001a">Supplementary material associated with this article can be found in the online version at doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.dib.2021.107697" id="interref0002">10.1016/j.dib.2021.107697</ext-link>.</p></fn></fn-group></back></article>